News & Updates

A study by the University of Hong Kong (HKU) has found that immune sera from mRNA-based BNT162b2 and inactivated CZ02 vaccine recipients have substantially reduced neutralizing antibody titres against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

A self-controlled case series reported by researchers from the University of Hong Kong has identified an increased risk of herpes zoster–related hospitalization associated with mRNA-based BNT162b2 and inactivated CZ02 vaccination against coronavirus disease 2019 (COVID-19).

An online survey of over 2,500 Hong Kong adolescents has identified knowing someone diagnosed with coronavirus disease 2019 (COVID-19), having at least one vaccinated parent, and receiving the influenza vaccine in the past year as three top predictors of COVID-19 vaccine acceptance.

A prospective cohort study by the University of Hong Kong comparing the reactogenicity of coronavirus disease 2019 (COVID-19) vaccines reports a lower risk of self-reported adverse reactions following vaccination with inactivated CZ02 compared with mRNA-based BNT162b2.

Serological assays for the coronavirus disease 2019 (COVID-19) sometimes show contradictory findings when compared with nasopharyngeal swab polymerase chain reaction (PCR) tests, according to a recent Singapore study. In particular, even PCR-negative patients with no known exposure could test positive for antibodies.

Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.

Ronapreve, also known as REGEN-COV, appears to reduce the risk of hospitalization or the need for additional treatment among COVID-19 patients when used in a real-world setting, a study has shown. The therapy is seen as a promising way to minimize the impact of SARS-CoV-2 infection on the public healthcare system.

Vaccines provide the best defense against COVID-19, but they are not without limitations. Acute infections still occur in some, especially those who are older, smokers, obese, or with type 2 diabetes (T2D), as reported in a study.

Therapy-naïve patients with haematological malignancies are able to mount a stronger immune response to the coronavirus disease 2019 (COVID-19), a recent study has found.

Older patients with COVID-19 may have an increased risk of being hospitalized for acute ischaemic stroke (AIS), particularly in the first 3 days following their COVID-19 diagnosis, according to a study presented at ISC 2022.